TACTICS

Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes

Coordinatore	STICHTING KATHOLIEKE UNIVERSITEIT    more  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Maarten Cognome: Van Langen Email: send email Telefono: +31 24 3618937 Fax: +31 24 3540529
Nazionalità Coordinatore	Netherlands [NL]
Sito del progetto	http://www.tactics-project.eu
Totale costo	7˙871˙883 €
EC contributo	6˙000˙000 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2011-two-stage
Funding Scheme	CP-FP
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-01-01   -   2016-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	STICHTING KATHOLIEKE UNIVERSITEIT  Organization address address: GEERT GROOTEPLEIN NOORD 9 city: NIJMEGEN postcode: 6525 EZ contact info Titolo: Mr. Nome: Maarten Cognome: Van Langen Email: send email Telefono: +31 24 3618937 Fax: +31 24 3540529	NL (NIJMEGEN)	coordinator	3˙093˙062.00
2	UNIVERSITAIR MEDISCH CENTRUM UTRECHT  Organization address address: HEIDELBERGLAAN 100 city: UTRECHT postcode: 3584 CX contact info Titolo: Prof. Nome: Sarah Cognome: Durston Email: send email Telefono: 31887558161	NL (UTRECHT)	participant	770˙734.00
3	KING'S COLLEGE LONDON  Organization address address: Strand city: LONDON postcode: WC2R 2LS contact info Titolo: Mr. Nome: Paul Cognome: Labbett Email: send email Telefono: +44 20 7848 8184 Fax: +44 20 7848 8187	UK (LONDON)	participant	406˙001.00
4	ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT  Organization address address: Square J 5 city: MANNHEIM postcode: 68159 contact info Nome: Simone Cognome: Fuchs Email: send email Telefono: +49 621 1703 1321 Fax: +49 621 1703 2915	DE (MANNHEIM)	participant	399˙480.00
5	The General Hospital Corporation  Organization address address: Fruit Street 55 city: "Boston, Massachusetts" postcode: 2114 contact info Titolo: Mr. Nome: John Cognome: Hureau Email: send email Telefono: +1 617 954 9566 Fax: +1 617 954 9892	US ("Boston, Massachusetts")	participant	325˙137.00
6	Concentris Research Management GmbH	DE	participant	300˙000.00
7	UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK  Organization address address: Western Road city: CORK postcode: - contact info Titolo: Dr. Nome: David Cognome: OÂ’connell Email: send email Telefono: +353 2149 03501 Fax: +353 2149 03506	IE (CORK)	participant	252˙181.00
8	TEL AVIV UNIVERSITY  Organization address address: RAMAT AVIV city: TEL AVIV postcode: 69978 contact info Titolo: Ms. Nome: Lea Cognome: Pais Email: send email Telefono: 97236408774 Fax: 97236409697	IL (TEL AVIV)	participant	214˙800.00
9	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE  Organization address address: The Old Schools, Trinity Lane city: CAMBRIDGE postcode: CB2 1TN contact info Titolo: Ms. Nome: Renata Cognome: Schaeffer Email: send email Telefono: +44 1223 333543 Fax: +44 1223 332988	UK (CAMBRIDGE)	participant	120˙000.00
10	GENOWAY S.A.  Organization address address: Avenue Jean Jaures 181 city: LYON postcode: 69362 contact info Titolo: Dr. Nome: Angelique Cognome: Heckmann Email: send email Telefono: +33 4 3765497	FR (LYON)	participant	100˙605.00
11	WOCKHARDT UK LTD  Organization address address: "ASH ROAD NORTH, WREXHAM INDUSTRIAL ESTATE" city: WREXHAM postcode: LL139UF contact info Titolo: Mr. Nome: Gordon Cognome: Urquhart Email: send email Telefono: +44 1978 669233	UK (WREXHAM)	participant	18˙000.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Compulsivity is characterized by a repetitive, irresistible urge to perform a behavior, the experience of loss of voluntary control over this intense urge, the diminished ability to delay or inhibit thoughts or behaviors, and the tendency to perform repetitive acts in a habitual or stereotyped manner. Compulsivity is a cross-disorder trait underlying phenotypically distinct psychiatric disorders that emerge in childhood (autism spectrum disorder, ASD; obsessive-compulsive disorder, OCD) or adolescence (substance abuse). Our approach integrates clinical data sets for ‘addictive’ (ADHD high risk for substance use), ‘anxious’ (OCD) and ‘stereotypical’ (ASD) compulsive behaviors with highly predictive animal models for new pharmacotherapy. In a series of ‘proof-of-concept’ studies, the cohesion of structural neuroimaging studies (MRI/DTI), neurochemistry (MRS/microdialysis), behavior, genetics (GWAS), proteomics and (Bayesian) machine learning tools in both male and female paediatric clinical populations and behavioral animal models will seek to better understand underlying mechanisms related to glutamate dysfunction in frontostriatal circuits and its remediation / prevention by early intervention studies with glutamate-based (riluzole and memantine) clinically used drugs. The leading drug-based interventions will be tested in pilot Phase IIb-like studies for ‘proof-of-principle’ efficacy in paediatric OCD and ASD populations. This approach will 1) establish predictive neural, genetic and molecular markers of compulsivity in pediatric populations; 2) provide evidence of disorder modifying pharmacologic strategies as a therapeutic approach; 3) develop a novel animal model for pharmaceutical screening and proof of concept studies, 4) build and valorize a translational biomarker compulsivity database and 5) provide pilot efficacy and safety data in paediatric clinical populations to support future large scale clinical trials according to these strategies.'